Bli medlem
Bli medlem

Du är här

2016-05-11

Enzymatica AB: Enzymatica's new rights issue completed - will be provided with SEK 60 million

This press release may not be published or distributed, directly or
indirectly, in or into the United States, Australia, Japan, Canada, Hong
Kong, New Zealand, Singapore or South Africa or any other jurisdiction where
such action is subject to legal restrictions.

The subscription period for Enzymatica AB (publ)'s ("Enzymatica" or the
"Company") rights issue with preferential rights for the Company's
shareholders ended on 6 May 2016 and the final result shows that
approximately 56 per cent of the rights issue was subscribed for through
preferential rights and that applications for subscription without
preferential rights corresponding to approximately 10 per cent of the rights
issue have been made. The remaining 34 per cent have been subscribed for by
underwriters. The Company will be provided with approximately SEK 60 million
before costs associated with the rights issue.

------------------------------------------------------------------------------------
|- We are very satisfied with the result of the new rights issue and particularly |
| of the interest to subscribe by shareholders, management, board of directors |
| and new long-term strategic investors. We will now have the possibility to |
| run the company according to our long-term strategy with international |
| expansion, says Fredrik Lindberg, CEO of Enzymatica. |
------------------------------------------------------------------------------------
The final result of Enzymatica's rights issue shows that approximately 15.3
million shares, corresponding to approximately 56 per cent of the offered
shares, were subscribed for through preferential rights. In addition,
applications for subscription of approximately 2.8 million shares,
corresponding to approximately 10 per cent of the offered shares, without
preferential rights have been made.

The remaining part of the rights issue, which amounts to approximately 9.4
million shares and corresponds to approximately 34 per cent of the offered
shares, have been subscribed for by underwriters who have undertaken to
subscribe for and pay for any part of the rights issue not subscribed for
with or without preferential rights.

Those who have subscribed for shares without preferential rights will be
allocated shares in accordance with the principles set out in the prospectus
published on 20 April 2016. Notices will be distributed to those who have
subscribed for shares without preferential rights shortly.

Through the rights issue, Enzymatica will be provided with approximately SEK
60 million before costs associated with the rights issue. The Company's share
capital will increase with approximately SEK 1,100,817.48 to approximately
SEK 2,935,513.27 and the total number of shares and votes will increase with
27,520,428 to 73,387,808 shares and votes when the rights issue has been
registered with the Swedish Companies Registration Office (Sw.Bolagsverket
).

The new shares are estimated to be eligible for trading at NASDAQ First North
as of May 25, 2016.

ABG Sundal Collier is financial advisor and Setterwalls Advokatbyrå is legal
advisor to Enzymatica in relation to the new issue with preemptive rights for
existing shareholders.

For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB

Tel: +46 708-86 53 70 | E-post:fredrik.lindberg@enzymatica.com

About Enzymatica AB

Enzymatica is a life science company who develops and sells medical device
products against infectious-related diseases. Over a short period the company
has developed a unique oral spray for colds, ColdZyme®, and launched it on
six markets. The product has become one of the leading articles for colds in
Swedish pharmacies. Enzymatica's strategy is to continue growing by
strengthening its position in existing markets and to expand to more
geographical markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North. For more
information, please visitwww.enzymatica.com.

Enzymatica's certified advisor is Erik Penser Bankaktiebolag.

Important information

The information in this press release does not contain or constitute an offer
to acquire, subscribe or otherwise trade in shares, subscription rights or
other securities in Enzymatica AB (publ).

This press release may not be published or distributed, directly or indirectly
in or into the United States, Australia, Japan, Canada, Hong Kong, New
Zeeland, Singapore or South Africa or any other jurisdiction where such
action is wholly or partially subject to legal restrictions or where such
action would require additional prospectuses, registrations or other actions
in addition to what follows from Swedish law. Nor may the information in this
press release be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or would require such requirements. Failure to
comply with this instruction may result in a violation of applicable
securities laws.

No subscription rights, interim shares or new shares have been registered, and
will not be registered, under the United States Securities Act of 1933
("Securities Act") or securities legislation in any other state or other
jurisdiction in the United States and may not be offered, subscribed, sold or
transferred, directly or indirectly within the United States, other than
pursuant to an exemption from the registration requirements of the Securities
Act and in accordance with securities laws in relevant state or other
jurisdiction in the United States.

This press release may contain forward-looking statements which reflect
Enzymatica AB (publ):s current view on future events and financial and
operational development. Words such as "intend", "expect", "anticipate",
"may", "believe", "plan", "estimate" and other expressions which imply
indications or predictions of future development or trends, and which are not
based on historical facts, are intended to identify forward-looking
statements. Forward-looking statements inherently involve both known and
unknown risks and uncertainties because they depend on future events and
circumstances. Forward-looking statements do not guarantee future results or
development and the real outcome could differ materially from the
forward-looking statements.

Press release (PDF)
http://hugin.info/160850/R/2011697/744905.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#2011697

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.